Nanoblades allow high-level genome editing in murine and human organoids
Victor Tiroille, Adrien Krug, Emma Bokobza, Michel Kahi, Mattijs Bulcaen, Marjolein M Ensinck, Maarten H Geurts, Delilah Hendriks, François Vermeulen, Frédéric Larbret, Alejandra Gutierrez-Guerrero, Yu Chen, Indra Van Zundert, Susana Rocha, Anne C Rios, Louise Medaer, Rik Gijsbers, Philippe E Mangeot, Hans Clevers, Marianne S Carlon, Frédéric Bost, Els Verhoeyen (see publication in Journal )Abstract
Genome engineering has become more accessible thanks to the CRISPR-Cas9 gene-editing system. However, using this technology in synthetic organs called “organoids” is still very inefficient. This is due to the delivery methods for the CRISPR-Cas9 machinery, which include electroporation of CRISPR-Cas9 DNA, mRNA, or ribonucleoproteins containing the Cas9-gRNA complex. However, these procedures are quite toxic for the organoids. Here, we describe the use of the “nanoblade (NB)” technology, which outperformed by far gene-editing levels achieved to date for murine- and human tissue-derived organoids. We reached up to 75% of reporter gene knockout in organoids after treatment with NBs. Indeed, high-level NB-mediated knockout for the androgen receptor encoding gene and the cystic fibrosis transmembrane conductance regulator gene was achieved with single gRNA or dual gRNA containing NBs in murine prostate and colon organoids. Likewise, NBs achieved 20%–50% gene editing in human organoids. Most importantly, in contrast to other gene-editing methods, this was obtained without toxicity for the organoids. Only 4 weeks are required to obtain stable gene knockout in organoids and NBs simplify and allow rapid genome editing in organoids with little to no side effects including unwanted insertion/deletions in off-target sites thanks to transient Cas9/RNP expression.